Abbott in July announced it has begun to compare three months of dual antiplatelet therapy (DAPT) to the current standard of 12 months after XIENCE everolimus-eluting coronary stent implantation.
“Limiting the duration of blood thinning medicine from 12 months to three months is particularly important for people at higher risk of bleeding due to factors such as older age, anemia and renal disease,” Roxana Mehran, MD, professor of medicine and director of interventional cardiovascular research and clinical trials at the Icahn School of Medicine at Mount Sinai, said in a statement. “The results of this study will help determine if doctors can safely reduce the amount of time that high bleeding-risk patients must take blood thinning medication after receiving a XIENCE stent to unblock coronary arteries.”
The study plans to enroll about 2,000 patients at 100 sites across the U.S. and Asia.
Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.